{
  "catalogId": "167e72c7-d5c1-4053-a650-06acb3424054",
  "name": "MINJUVI 200 mg",
  "status": "",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "169 96 37059 00",
  "treatmentDescriptions": "MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).",
  "termsOfIssue": "Prescription required",
  "form": "powder for concentrate for solution for infusion",
  "route": "i.v",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "TAFASITAMAB/VIAL",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01FX12",
      "name": "TAFASITAMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת ",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "MINJUVI 200 MG 1 VIAL",
      "manufacturer": {
        "name": "מדיסון",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "60",
      "storageConditions": "",
      "codes": {
        "moh": "9021",
        "yarpa": "44052"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 2741.82759,
        "retailMargin": 10.0,
        "maxRetailPrice": 3016.010349,
        "maxPriceWithVAT": 3558.892054
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T05:25:33.544737"
  }
}